[Rimactan. Experimental studies and clinical experience].
D000818:Animals; D003881:Dermatomycoses / Q000188:drug therapy; D004352:Drug Resistance, Microbial; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D006168:Guinea Pigs; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D011472:Prostatitis / Q000188:drug therapy; D011711:Pyoderma / Q000188:drug therapy; D011817:Rabbits; D051381:Rats; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D014526:Urethritis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy*
D012293:Rifampin
Rimactan. Experimentelle Untersuchungen und klinische Erfahrungen.